Eduardo Martinez's questions to CareDx Inc (CDNA) leadership • Q4 2024
Question
Eduardo Martinez of H.C. Wainwright asked for more details on the medication therapy management program, the timeline for the AlloHeme product, and the company's interest in xenotransplantation partnerships.
Answer
CEO John Hanna detailed a two-pronged pharmacy strategy: digital tools with text reminders and a patient app, and a high-touch specialty pharmacy program for complex cases. For AlloHeme, he noted the ACROBAT trial is a 2-year study, nearly enrolled, with a launch discussion pending trial completion and Medicare submission. He also confirmed CareDx is already active in xenotransplantation, with a specific monitoring product and partnerships with companies in the space.